Although changes in plasma and/or placental kisspeptin levels are also observed in maternal hypothyroidism [32], preeclampsia, miscarriage, and gestational diabetes [48,49,50,51,52,53], in the present study, kisspeptin treatment was able to suppress placental and decidual activation of the inflammasome-NLRP3-pyroptosis pathway. Here, NLRP3 is linked to preeclampsia.